Differential expression and regulation of the cAMP‐selective phosphodiesterase type 4A splice variants in rat brain by chronic antidepressant administration
- 27 September 2005
- journal article
- Published by Wiley in European Journal of Neuroscience
- Vol. 22 (6) , 1463-1475
Abstract
Chronic antidepressant treatment up‐regulates the cAMP cascade in limbic brain regions, suggesting that activation of this pathway contributes to the therapeutic efficacy of antidepressants. A role for cAMP signaling is supported by the finding that rolipram, a selective inhibitor of cAMP‐specific phosphodiesterases type 4 (PDE4), has antidepressant efficacy in behavioral models of depression and in clinical trials. To elucidate further the role of PDE4 isozymes, we characterized the expression and regulation of PDE4A splice variants (i.e. PDE4A1, PDE4A5, PDE4A8 and PDE4A10) in rat brain by chronic antidepressant treatment. Initial in situ hybridization studies (ISH) revealed high levels of PDE4A1 mRNA in medial septum, diagonal band, olfactory system, hippocampus and cerebellum. PDE4A5 mRNA expression was restricted to the olfactory nuclei, deep cortical layers, dentate and CA1 pyramidal layers. PDE4A10 mRNA was localized in the dentate gyrus and CA1 pyramidal layers. PDE4A8 mRNA was absent in rat brain. We determined the influence of chronic fluoxetine or electroconvulsive seizure (ECS) treatments on PDE4A splice variants expression in various brain regions. ISH analysis indicated that chronic fluoxetine or ECS treatments significantly increased PDE4A1, but not PDE4A5 or PDE4A10, mRNA levels in frontal and parietal cortices. ECS increased PDE4A5 levels in the anterior cingulate and frontoparietal cortices, CA1 and dentate gyrus, whereas chronic fluoxetine or ECS treatment increased PDE4A10 levels in the hippocampus. The differential up‐regulation of PDE4A splice variants suggests compensatory region‐specific responses to the antidepressant‐induced increase in cAMP signaling and suggests that these splice variants may be relevant as targets for antidepressant intervention.Keywords
This publication has 40 references indexed in Scilit:
- Attenuation of the Activity of the cAMP-specific Phosphodiesterase PDE4A5 by Interaction with the Immunophilin XAP2Journal of Biological Chemistry, 2003
- TAPAS-1, a Novel Microdomain within the Unique N-terminal Region of the PDE4A1 cAMP-specific Phosphodiesterase That Allows Rapid, Ca2+-triggered Membrane Association with Selectivity for Interaction with Phosphatidic AcidJournal of Biological Chemistry, 2002
- Effects of Repeated Antidepressant Treatment on Type 4A Phosphodiesterase (PDE4A) in Rat BrainJournal of Neurochemistry, 2000
- Challenge of human Jurkat T-cells with the adenylate cyclase activator forskolin elicits major changes in cAMP phosphodiesterase (PDE) expression by up-regulating PDE3 and inducing PDE4D1 and PDE4D2 splice variants as well as down-regulating a novel PDE4A splice variantBiochemical Journal, 1997
- The SH3 domain of Src tyrosyl protein kinase interacts with the N-terminal splice region of the PDE4A cAMP-specific phosphodiesterase RPDE-6 (RNPDE4A5)Biochemical Journal, 1996
- Alternative Splicing of cAMP-specific Phosphodiesterase mRNA TranscriptsJournal of Biological Chemistry, 1996
- Identification, characterization and regional distribution in brain of RPDE-6 (RNPDE4A5), a novel splice variant of the PDE4A cyclic AMP phosphodiesterase familyBiochemical Journal, 1995
- Identification and characterization of the type-IVA cyclic AMP-specific phosphodiesterase RD1 as a membrane-bound protein expressed in cerebellumBiochemical Journal, 1995
- Differential CNS expression of alternative mRNA isoforms of the mammalian genes encoding cAMP-specific phosphodiesterasesGene, 1994
- Is Phosphodiesterase inhibition a new mechanism of antidepressant action?European Archives of Psychiatry and Clinical Neuroscience, 1988